Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Saved in:
| Title: | Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. |
|---|---|
| Authors: | Remon, J.1 (AUTHOR), Besse, B.1 (AUTHOR), Aix, S. Ponce2 (AUTHOR), Callejo, A.3 (AUTHOR), Al-Rabi, K.4 (AUTHOR), Bernabe, R.5 (AUTHOR), Greillier, L.6 (AUTHOR), Majem, M.7 (AUTHOR), Reguart, N.8 (AUTHOR), Monnet, I.9 (AUTHOR), Cousin, S.10 (AUTHOR), Garrido, P.11 (AUTHOR), Robinet, G.12 (AUTHOR), Garcia Campelo, R.13 (AUTHOR), Madroszyk, A.14 (AUTHOR), Mazières, J.15 (AUTHOR), Curcio, H.16 (AUTHOR), Wasąg, B.17 (AUTHOR), Pretzenbacher, Y.18 (AUTHOR), Fournier, B.18 (AUTHOR) |
| Source: | Annals of Oncology. May2023, Vol. 34 Issue 5, p468-476. 9p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.02.012 |
